On August 25, LEADS BIOLABS-B rose 5.14% in regular trading, trading at HK$72.4/share, with turnover of approximately HK$28.4 million. The stock gained on news that its core drug candidate Vilixin (Opamtistomig, PD-L1/4-1BB bispecific antibody, LBL-024) has advanced its Phase II clinical study for first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) into the expansion stage.

According to the company announcement, the study completed its safety run-in period and progressed based on positive efficacy signals along with a favorable safety and tolerability profile. The company also noted that three proof-of-concept studies for Vilixin in first-line extra-pulmonary neuroendocrine carcinoma, small cell lung cancer, and biliary tract cancer have all completed patient enrollment, with the EP-NEC indication already advancing into a confirmatory Phase III clinical stage.

This milestone adds to a series of recent clinical catalysts, including the drug's inclusion in priority review for EP-NEC, six research abstracts accepted at ESMO, and expansion-stage entries in hepatocellular carcinoma and biliary tract cancer indications, collectively reinforcing the breadth of Vilixin's commercial pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)